Google
VINC — VINCERX PHARMA, INC. COMMON STOCK (Healthcare >> Biotechnology)
VINC FAQ
What is VINC's ROE?
VINCERX PHARMA, INC. COMMON STOCK reports a Return on Equity (ROE) of -1,096.08%.
What is VINC's dividend yield?
VINCERX PHARMA, INC. COMMON STOCK offers a dividend yield of 0.00%.
What is VINC's Deepscope Quality Score?
Deepscope rates VINC's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy VINC?
Deepscope's AI Timing Score for VINC is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does VINC belong to?
VINCERX PHARMA, INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 0.01
Price
0.00
(0.00%)
Day Change
|
|
|---|
VINC, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 92 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.01 |
| PBV / Sector |
0.03 / 4.63
GREAT
|
| Earning Per Share | -4.23 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
72.582285000000
GOOD
|
| Average 1W Daily Value |
35.457120000000
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
43% |
| ポイントになる統計 |
|
45% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:08:31 |
| Symbol | VINC |
| Name | VINCERX PHARMA, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 5.23 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 0.07 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1825 S. Grant Street, San Mateo, CA, United States, 94402
Phone: 650 800 6676
Website: https://vincerx.com
Sector: Healthcare >> Biotechnology
Description: Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and provides CellTrapper technology for use in reduction of payload cellular permeability. The company develops VIP943, an antibody drug conjugate in Phase 1 dose-escalation study for relapsed/refractory acute myeloid leukemia, higher-risk MDS, and B-cell acute lymphoblastic leukemia; VIP236, an SMDC, which is in Phase 1 dose-escalation study for the treatment of patients with advanced or metastatic solid tumors; and VIP924, an anti-CXCR5 ADC that leverages the same effector chemistry in preclinical studies for b-cell malignancies. It has a collaboration with the National Institutes of Health for the Phase 1 dose-escalation of enitociclib, a highly selective cyclin-dependent kinase 9 inhibitor. The company was formerly known as Vincera Pharma, Inc. and changed its name to Vincerx Pharma, Inc. in January 2021. Vincerx Pharma, Inc. was founded in 2019 and is headquartered in San Mateo, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
